About Guardant Health
What Guardant Health is building
Technologies used at Guardant Health
React
JavaCompany culture
Blaze a trail.
Be solution oriented
Be stronger together.
Treat each other with respect
Funding rounds
Total Funding
Last funding round type
Company type
Guardant Health news and updates
Guardant Health launches data on Shield Test; Grail
Those include Guardant Health, which recently released data on its Shield Test; Grail, which has been selling its test as a prescription lab-developed test; and Freenome, which completed enrollment earlier this year for a 40,000-person trial of its colorectal cancer test for which it expects results in mid-2023.
Dec 22, 2022 | medtechdive.comGuardant Health is developing Guardant Reveal
Through the collaboration, Guardant and Komen will work together on the design of studies evaluating Guardant Reveal in patients with early-stage breast cancer, including getting input from patient advocates to help guide trial design.
Dec 21, 2022 | precisiononcologynews.comGuardant Health launched GuardantINFINITY on Sep 9th 22'.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development.
Sep 8, 2022 | otcdynamics.comSimon left Guardant Health as senior vice president, biopharma business development on Aug 1st 22'.
Mr. Simon joins Revolution Medicines from Guardant Health where he most recently served as the company’s senior vice president, biopharma business development.
Sep 1, 2022 | globenewswire.comMerck KGaA partners with Guardant Health
Luckily for Merck KGaA, the German pharma is getting a head start in that department through a partnership with blood-testing company Guardant Health.
Aug 30, 2022 | fiercebiotech.comGuardant Health launched liquid biopsy service in Europe on Jul 6th 22'.
(Getty Images) After launching its first liquid biopsy service in Europe earlier this year, the cancer test developer Guardant Health is taking new steps to offer its comprehensive genomic profiling technology in China.
Jul 6, 2022 | fiercebiotech.comEpic Systems partnered with Guardant Health on Apr 4th 22'.
On April 4, 2022, Epic announced a partnership with Guardant Health, Inc. to streamline the ability of clinicians to order from a broad portfolio of cancer tests and then directly access results.
Apr 10, 2022 | healthtechresourcesinc.comGuardant Health Inc. launches Smart Liquid Biopsy
Furthermore, Guardant announced the release of Smart Liquid Biopsy, boosting current screening performance of 360 CDx by 100 folds.
Jan 1, 2022 | art25capital.comGuardant Health is developing LUNAR-2 liquid biopsy
Guardant Health has developed several precision oncology tests, including the LUNAR-2 liquid biopsy for early CRC detection in average-risk individuals.
Jan 1, 2022 | bestinau.netIllumina, Inc. filed suit against Guardant Health on Mar 17th 22'.
· Illumina ( ILMN ) is suing rival liquid biopsy player Guardant Health ( GH ), claiming that the latter’s patents are based on work stolen from the genomics giant.
Jan 1, 2022 | investrade.comGuardant Health has issues with allegedly misappropriating its trade secrets and breach of contract
Illumina has taken the co-CEOs of Guardant Health to court for allegedly misappropriating its trade secrets and breach of contract.
Jan 1, 2022 | medtechdive.comGuardant Health launched LUNAR assay on Jan 1st 19'.
For instance, in January 2019, Guardant Health, Inc. announced it has launched LUNAR assay, which is a blood-based assay intended to detect early-stage cancer and recurrence of disease.
Jan 1, 2022 | digitaljournal.comGuardant Health had issues with co-founders hijacked confidential trade secrets on Mar 16th 22'.
San Diego’s Illumina filed a lawsuit last week against Guardant Health, claiming its co-founders hijacked confidential trade secrets while working at Illumina to establish the intellectual property foundation for their own new company.
Jan 1, 2022 | sandiegouniontribune.comPolkadot PR Pty Ltd partners with Guardant Health
"Polkadot PR Pty Ltd is very excited to be partnering with Guardant Health, a global leader in CGP testing, to bring a world-class testing platform to China.
Jan 1, 2022 | prnasia.comPR Newswire partners with Guardant Health
"PR Newswire is very excited to be partnering with Guardant Health, a global leader in CGP testing, to bring a world-class testing platform to China.
Jan 1, 2022 | prnewswire.co.ukMedical Buyer partners with Guardant Health
“Medical Buyer is very excited to be partnering with Guardant Health, a global leader in CGP testing, to bring a world-class testing platform to China.
Jan 1, 2022 | medicalbuyer.co.inGuardant Health hires Steve Krognes as board of directors
Guardant Health has appointed Steve Krognes to its board of directors.
Jan 1, 2022 | genomeweb.comLunit Inc. partners with Guardant Health
Lunit has partnered with GE Healthcare, Fujifilm, Philips and Guardant Health to deploy its AI products.
Jan 1, 2022 | nvidia.comGuardant Health is developing AI biomarkers
The company has also signed a joint research agreement with global biotechnology companies, including Guardant Health, to develop AI biomarkers.
Jan 1, 2022 | koreabiomed.comGuardant Health launches Guardant Reveal
Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Guardant Reveal™, the only tissue-free test for the detection of residual and recurrent disease for colorectal cancer (CRC), is now available for patients with breast and lung cancers.
Jan 1, 2022 | stockhouse.comGuardant Health had issues with patent infringement case on Nov 14th 20'.
Guardant Health Inc.’s patent infringement case against Foundation Medicine Inc. over cancer testing technology is heading to trial in Delaware federal district court next month, after twice being delayed.
Jan 6, 2020 | bloomberglaw.comGuardant Health is developing GuardantOMNI
Guardant Health also will develop a plasma-based tumor mutational burden (TMB) score CDx test using GuardantOMNI to predict response to AstraZeneca immunotherapy and targeted therapies within its oncology portfolio.
Dec 13, 2018 | rdmag.com